Alexion Pharmaceuticals has successfully acquired two new drug approvals that will expand its revenue base beyond its flagship drug Soliris, but analysts are showing little confidence in the underwhelming launches.
The ultra-rare disease company announced earnings Feb 3, admitting that the launches of its two recently-approved drugs, Strensiq (asfotase alfa)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?